Internal Medicine, Hematology & Oncology · Shreveport, LA
NPI
1528279965
Since 2007
Specialty
Internal Medicine, Hematology & Oncology
Code 207RH0003X
Group practices
1
Medicare group memberships
Hospitals
5
Hospital affiliations
1455 E Bert Koun Loop # 101
Shreveport, LA, 71105
Phone (318) 798-4424
Groups this clinician bills Medicare through
Medicare paid, 2024
$9.4M
398,318 services
Medicare patients, 2024
1,182
Average age 75
Drug cost, 2024
$28.6M
6,119 prescriptions
Company payments, 2025
$8,435
From 48 companies
Procedures and visits billed to Original Medicare, 2024
In 2024, the most common Medicare service billed by Kirtan N Koticha was code J9271 (injection, pembrolizumab, 1 mg), 47,000 times for 29 patients. In total Kirtan N Koticha billed 398,318 services in 174 codes, and Medicare paid $9.4M.
| Code |
|---|
Official US government data: the national provider registry and Medicare enrollment records, linked by NPI. Last update of this record: 2018-10-08.
| Setting |
|---|
| Services |
|---|
| Patients |
|---|
| Paid per service |
|---|
| Medicare paid |
|---|
| J9271 Injection, pembrolizumab, 1 mg | Office | 47,000 | 29 | $44.68 | $2.1M |
| J0897 Injection, denosumab, 1 mg | Office | 30,840 | 197 | $20.39 | $629K |
| Q0138 Injection, ferumoxytol, for treatment of iron deficiency anemia, 1 mg (non-esrd use) | Office | 30,600 | 23 | $0.30 | $9,077 |
| J1437 Injection, ferric derisomaltose, 10 mg | Office | 24,700 | 179 | $15.76 | $389K |
| J1453 Injection, fosaprepitant, 1 mg | Office | 18,750 | 28 | $0.11 | $2,080 |
| J9144 Injection, daratumumab, 10 mg and hyaluronidase-fihj | Office | 17,640 | 16 | $38.62 | $681K |
| J0885 Injection, epoetin alfa, (for non-esrd use), 1000 units | Office | 7,240 | 28 | $6.39 | $46K |
| J1602 Injection, golimumab, 1 mg, for intravenous use | Office | 6,550 | 11 | $9.13 | $60K |
| J1745 Injection, infliximab, excludes biosimilar, 10 mg | Office | 3,930 | 21 | $24.60 | $97K |
| J0185 Injection, aprepitant, 1 mg | Office | 3,900 | 11 | $1.37 | $5,357 |
| 36415 Venipuncture Blood Collection | Office | 3,857 | 1,006 | $8.63 | $33K |
| 85025 Blood Count | Office | 3,584 | 871 | $7.58 | $27K |
| J9312 Injection, rituximab, 10 mg | Office | 3,360 | 11 | $61.42 | $206K |
| 80053 Clinical Chemistry | Office | 3,105 | 861 | $10.30 | $32K |
| J1100 Injection, dexamethasone sodium phosphate, 1 mg | Office | 2,384 | 47 | $0.09 | $213 |
By year: 2022 $6.1M for 441,631 services; 2023 $7.2M for 486,088 services; 2024 $9.4M for 398,318 services.
Lab tests billed to Medicare, 2024
| Test code | Tests | Patients | Paid per test | Medicare paid |
|---|---|---|---|---|
| 36415 Venipuncture Blood Collection | 3,857 | 1,006 | $8.63 | $33K |
| 85025 Blood Count | 3,584 | 871 | $7.58 | $27K |
| 80053 Clinical Chemistry | 3,105 | 861 | $10.30 | $32K |
| 83550 Clinical Chemistry | 1,158 | 555 | $8.56 | $9,918 |
| 83540 Clinical Chemistry | 1,158 | 555 | $6.34 | $7,337 |
| 82728 Clinical Chemistry | 1,154 | 556 | $13.34 | $15K |
| 83615 Clinical Chemistry | 647 | 350 | $5.91 | $3,822 |
| 80048 Clinical Chemistry | 240 | 174 | $8.29 | $1,990 |
| 84443 Clinical Chemistry | 200 | 138 | $16.46 | $3,292 |
| 84153 Clinical Chemistry | 156 | 51 | $17.84 | $2,783 |
Medicare prescription drug claims, 2024
In 2024, the drug Kirtan N Koticha prescribed most often to Medicare patients was Eliquis (Apixaban), with 315 prescriptions and refills. In total Kirtan N Koticha wrote 6,119 Medicare prescriptions that cost $28.6M.
| Drug | Claims | 30-day fills | Patients | Cost |
|---|---|---|---|---|
| Eliquis Apixaban | 315 | 383 | 60 | $208K |
| Procrit Epoetin Alfa | 292 | 292 | 83 | $1.2M |
| Hydrocodone-Acetaminophen Hydrocodone/Acetaminophen | 194 | 194 | 57 | $3,941 |
| Ondansetron Odt Ondansetron | 179 | 189 | 104 | $2,676 |
| Darzalex Faspro Daratumumab-Hyaluronidase-Fihj | 178 | 179 | 30 | $2.9M |
| Letrozole Generic | 177 | 326 | 32 | $2,919 |
| Xarelto Rivaroxaban | 171 | 209 | 27 | $112K |
| Prolia Denosumab | 167 | 993 | 109 | $283K |
| Palonosetron Hcl Generic | 160 | 160 | 44 | $21K |
| Fosaprepitant Dimeglumine Generic | 106 | 106 | 31 | $11K |
| Fulphila Pegfilgrastim-Jmdb | 103 | 103 | 30 | $274K |
| Gabapentin Generic | 103 | 109 | 24 | $710 |
| Promethazine Hcl Generic | 102 | 117 | 57 | $1,385 |
| Potassium Chloride Generic | 92 | 116 | 26 | $1,154 |
| Hydroxyurea Generic | 83 | 139 | 17 | $1,870 |
Brand drugs: 3,137 claims; generic drugs: - claims; opioid claims: 358.
Money and other things of value reported by the companies
In 2025, drug and medical device companies paid Kirtan N Koticha $8,435 ($8,435 in general payments such as food, travel and fees) from 48 companies. The largest payer was OnMark, Inc. with $3,851.
| Company | Payments | Amount |
|---|---|---|
| OnMark, Inc. | 10 | $3,851 |
| Janssen Biotech, Inc. JNJ | 23 | $651 |
| Genentech USA, Inc. ROG.SW | 19 | $381 |
| Pfizer Inc. PFE | 17 | $279 |
| AstraZeneca Pharmaceuticals LP AZN | 13 | $276 |
| Bayer Healthcare Pharmaceuticals Inc. BAYN.DE | 11 | $245 |
| Merck Sharp & Dohme LLC MRK | 11 | $217 |
| Celgene Corporation BMY | 9 | $175 |
| Stemline Therapeutics Inc. | 4 | $163 |
| Astellas Pharma US Inc 4503.T | 8 | $160 |
Official US government data on Original Medicare services, Medicare prescription drug plans and the payments drug and device companies must report. Services with fewer than 11 patients and drugs with fewer than 11 claims are not published. Procedure codes are shown by number with their public category.